Connor Clark & Lunn Investment Management Ltd. Purchases 189,775 Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)

Key Points

• Connor Clark & Lunn Investment Management Ltd. increased its holdings in Aurinia Pharmaceuticals by 34.1%, owning 746,229 shares valued at approximately $6 million.
• Several institutional investors also boosted their stakes in Aurinia Pharmaceuticals, with notable increases including Deutsche Bank AG (76.7%) and GSA Capital Partners LLP (656.2%).
• Aurinia Pharmaceuticals reported a net margin of 23.31% and revenues exceeding analyst expectations at $70.01 million for the last quarter.

Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP by 34.1% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 746,229 shares of the biotechnology company's stock after purchasing an additional 189,775 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 0.55% of Aurinia Pharmaceuticals worth $6,000,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Deutsche Bank AG boosted its holdings in shares of Aurinia Pharmaceuticals by 54.8% during the 4th quarter. Deutsche Bank AG now owns 142,869 shares of the biotechnology company's stock valued at $1,283,000 after purchasing an additional 50,575 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Aurinia Pharmaceuticals by 3.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 76,314 shares of the biotechnology company's stock valued at $685,000 after purchasing an additional 2,887 shares during the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in shares of Aurinia Pharmaceuticals during the 1st quarter valued at about $86,000. GAMMA Investing LLC boosted its holdings in shares of Aurinia Pharmaceuticals by 56.1% during the 1st quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock valued at $39,000 after purchasing an additional 1,744 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Aurinia Pharmaceuticals by 19.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 52,098 shares of the biotechnology company's stock valued at $468,000 after purchasing an additional 8,350 shares during the last quarter. Institutional investors own 36.83% of the company's stock.

Aurinia Pharmaceuticals Trading Up 1.5%

Shares of NASDAQ:AUPH traded up $0.18 during trading on Friday, reaching $12.27. The company's stock had a trading volume of 2,262,809 shares, compared to its average volume of 2,793,175. The company has a current ratio of 5.23, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18. Aurinia Pharmaceuticals Inc has a 12 month low of $5.51 and a 12 month high of $12.48. The firm's 50 day simple moving average is $9.08 and its two-hundred day simple moving average is $8.39. The stock has a market capitalization of $1.62 billion, a PE ratio of 28.54 and a beta of 1.23.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last announced its quarterly earnings results on Thursday, July 31st. The biotechnology company reported $0.16 EPS for the quarter, missing analysts' consensus estimates of $0.17 by ($0.01). Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. The business had revenue of $70.01 million during the quarter, compared to the consensus estimate of $64.27 million. On average, research analysts predict that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. HC Wainwright reissued a "buy" rating and set a $17.00 price objective on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th. Royal Bank Of Canada upped their target price on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the company an "outperform" rating in a research report on Friday, August 1st.

Insider Transactions at Aurinia Pharmaceuticals

In other news, Director Kevin Tang acquired 200,000 shares of the firm's stock in a transaction on Tuesday, August 5th. The stock was acquired at an average price of $11.68 per share, with a total value of $2,336,000.00. Following the completion of the purchase, the director directly owned 11,329,500 shares in the company, valued at approximately $132,328,560. This trade represents a 1.80% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have bought a total of 1,300,000 shares of company stock valued at $13,590,000 over the last ninety days. 12.20% of the stock is owned by company insiders.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.